The Role of Vaccines for HPV-Related Head and Neck Cancers

Part of the Head and Neck Cancer Clinics book series (HNCC)


Several lines of evidence highlight the importance of a functioning immune system in controlling human papillomavirus (HPV) infection and its associated neoplasms. Harnessing the immune system to both prevent and treat HPV infections has therefore been an area of significant research effort, innovation and progress over the past decades. Although much of the research performed thus far has been on genital HPV infections, the interaction between oral HPV infection and the immune system are beginning to be explored.


Cervical Intraepithelial Neoplasia Quadrivalent Vaccine Therapeutic Vaccination Therapeutic Vaccination Strategy 


  1. 1.
    Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011;377:932–40.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Bourgault Villada I, Moyal Barracco M, Ziol M, et al. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res. 2004;64:8761–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Kreimer AR, Pierce Campbell CM, Lin HY, et al. Incidence and clearance of oral oncogenic human papillomavirus (HPV) in men: the HIM cohort study. Lancet. 2013;382:877–87.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    D’Souza G, Griffioen AM, Kluz N, et al. Oral HPV prevalence, six-month persistence and incidence among high-risk young adults. In: 28th international papillomavirus conference, San Juan, Puerto Rico; 2012. p. 215.Google Scholar
  5. 5.
    Peitsaro P, Johansson B, Syrjänen S. Integrated human papillomavirus type-16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol. 2002;40:886–91.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer. 1999;80:2008–18.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007;212:356–67.PubMedCrossRefGoogle Scholar
  8. 8.
    Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res. 2007;86:104–14.PubMedCrossRefGoogle Scholar
  9. 9.
    Howley PM. Role of the human papillomaviruses in human cancer. Cancer Res. 1991;51(18 Suppl):5019s–22.PubMedGoogle Scholar
  10. 10.
    Paternoster DM, Cester M, Resente C, et al. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc. 2008;40:1877–80.PubMedCrossRefGoogle Scholar
  11. 11.
    D’Souza G, Fakhry C, Sugar EA, et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer. 2007;121:143–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Fruchter RG, Maiman M, Sedlis A, et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol. 1996;87:338–44.PubMedCrossRefGoogle Scholar
  13. 13.
    Moscicki AB, Ellenberg JH, Farhat S, et al. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis. 2004;190:37–45.PubMedCrossRefGoogle Scholar
  14. 14.
    Heard I, Tassie JM, Kazatchkine MD, et al. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS. 2002;16:1799–802.PubMedCrossRefGoogle Scholar
  15. 15.
    Best SR, Peng S, Juang CM, et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T-cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 2009;27:5450–9.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Cheng WF, Hung CF, Chai CY, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001;108:669–78.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology. 2009;384:410–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. 2001;61:1934–40.PubMedGoogle Scholar
  20. 20.
    Jochmus-Kudielka I, Schneider A, Braun R, et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst. 1989;81:1698–704.PubMedCrossRefGoogle Scholar
  21. 21.
    D’Souza G, Kreimer AR, Viscidi R, et al. Case–control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:944–56.Google Scholar
  22. 22.
    Anderson KS, Wong J, D’Souza G, et al. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer. 2011;104:1896–905.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Kreimer AR, Johansson M, Waterboer T, et al. An evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. In: 28th international papillomavirus conference 2012; San Juan, Puerto Rico.Google Scholar
  24. 24.
    Matloubian M, Concepcion RJ, Ahmed R. CD4+ T-cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol. 1994;68:8056–63.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Welters MJ, de Jong A, van den Eeden SJ, et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 2003;63:636–41.PubMedGoogle Scholar
  26. 26.
    de Jong A, van Poelgeest MI, van der Hulst JM, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 2004;64:5449–55.PubMedCrossRefGoogle Scholar
  27. 27.
    Nakagawa M, Stites DP, Farhat S, et al. Cytotoxic T-lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis. 1997;175:927–31.PubMedCrossRefGoogle Scholar
  28. 28.
    Hemminki K, Chen B. Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol Biomarkers Prev. 2006;15:1413–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002;2:59–65.PubMedCrossRefGoogle Scholar
  30. 30.
    Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24 Suppl 1:S16–22.PubMedCrossRefGoogle Scholar
  31. 31.
    Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733–41.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Woodworth CD. HPV innate immunity. Front Biosci. 2002;7:d2058–71.PubMedCrossRefGoogle Scholar
  33. 33.
    Ashrafi GH, Haghshenas MR, Marchetti B, et al. E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer. 2005;113:276–83.PubMedCrossRefGoogle Scholar
  34. 34.
    Hasan UA, Bates E, Takeshita F, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol. 2007;178:3186–97.PubMedCrossRefGoogle Scholar
  35. 35.
    Huang SM, McCance DJ. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol. 2002;76:8710–21.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Lee SJ, Cho YS, Cho MC, et al. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J Immunol. 2001;167:497–504.PubMedCrossRefGoogle Scholar
  37. 37.
    Barnard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology. 1999;259:305–13.PubMedCrossRefGoogle Scholar
  38. 38.
    Li S, Labrecque S, Gauzzi MC, et al. The human papillomavirus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene. 1999;18:5727–37.Google Scholar
  39. 39.
    Nees M, Geoghegan JM, Hyman T, et al. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol. 2001;75:4283–96.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Zhou J, Sun XY, Stenzel DJ, et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185:251–7.Google Scholar
  41. 41.
    Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116:1167–73.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43.Google Scholar
  43. 43.
    Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.CrossRefGoogle Scholar
  44. 44.
    GlaxoSmithKline. Clinical trial NCT00423046. Cited 2012; Available from:
  45. 45.
    Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364:401–11.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87:544–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years—united states, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:1117–23.Google Scholar
  48. 48.
    Mullins TL, Zimet GD, Rosenthal SL, et al. Adolescent perceptions of risk and need for safer sexual behaviors after first human papillomavirus vaccination. Arch Pediatr Adolesc Med. 2012;166:82–8.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Sanders Thompson VL, Arnold LD, Notaro SR. African american parents’ HPV vaccination intent and concerns. J Health Care Poor Underserved. 2012;23:290–301.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Pourat N, Jones JM. Role of insurance, income, and affordability in human papillomavirus accination. Am J Manag Care. 2012;18:320–30.PubMedGoogle Scholar
  51. 51.
    Bogaards JA, Coupé VM, Xiridou M, et al. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology. 2011;22:505–15.PubMedCrossRefGoogle Scholar
  52. 52.
    Centers for Disease Control and Prevention (CDC). Genital HPV infection – fact sheet. 2011; Available from:
  53. 53.
    Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the united states. J Clin Oncol. 2011;29:4294–301.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Cheng WF, Hung CF, Chen CA, et al. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine. 2005;23:3864–74.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Peng S, Lyford-Pike S, Akpeng B, et al. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother. 2013;62:171–82.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361:1838–47.PubMedCrossRefGoogle Scholar
  57. 57.
    De Vo svan Steenwijk PJ, Ramwadhdoebe TH, Löwik MJ, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother. 2012;61:1485–92.Google Scholar
  58. 58.
    Trimble CL, Peng S, Kos F, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009;15:361–7.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Center SKCC. Clinical trial NCT01493154 – safety study of HPV DNA vaccine to treat head and neck cancer patients. Available from:
  60. 60.
    Loddenkemper C, Hoffmann C, Stanke J, et al. Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer. Cancer Sci. 2009;100:1112–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Welters MJ, Kenter GG, de Vo svan Steenwijk PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A. 2010;107:11895–9.PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Emens LA, Asquith JM, Leatherman JM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol. 2009;27:5911–8.PubMedCentralPubMedCrossRefGoogle Scholar
  63. 63.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.PubMedCentralPubMedCrossRefGoogle Scholar
  64. 64.
    Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.PubMedCrossRefGoogle Scholar

Copyright information

© Carole Fakhry, Gypsyamber D’Souza, Rehan Kazi and Raghav C. Dwivedi 2015

Authors and Affiliations

  1. 1.Department of Otolaryngology – Head and Neck SurgeryThe Johns Hopkins School of MedicineBaltimoreUSA
  2. 2.Department of SurgeryMassachusetts General Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations